Tweet
The new NEXTflex Cell Free DNA-Seq Kit is optimized to produce libraries from 1 ng of circulating tumor DNA (ctDNA) or cell free fetal DNA (cffDNA), in two hours or less. This low-input library preparation kit delivers high coverage quality and reduced bias for Illumina sequencing applications. The NEXTflex Cell Free DNA-Seq Kit contains a high fidelity enzyme which exhibits minimal GC bias and produces uniform coverage of difficult to sequence DNA. The patent pending Enhanced Adapter Ligation Technology incorporated into the ligation step offers the highest ligation efficiency available, resulting in greater library diversity and a larger number of unique sequencing reads. Up to 192 unique adapter barcodes are available, facilitating high-throughput multiplexing. Protocols for automating library prep using the NEXTflex Cell Free DNA-Seq Kit are also available, for Bioo Scientific's SEQBOT™ NGS Library Prep Automation Platform, the Beckman Biomek® FX and Biomek® FXP Laboratory Automation Workstations, and the Sciclone NGS, Sciclone NGSx and Sciclone G3 platforms.
-
Last edited by Bioo Scientific; 10-23-2014, 09:00 AM. -
The NEXTflex Cell Free DNA-Seq Kit is designed for making NGS libraries from low-input cfDNA or ctDNA samples. Visit our website for data demonstrating the use of this kit to produce high-quality informative libraries from cell-free DNA extracted from plasma. -
Do you have any data that demonstrates superiority of your ligation technology in comparison to other similar products? And can you explain to your potential customers why your library protocols are not freely avaible online like other vendors?Last edited by nucacidhunter; 10-15-2014, 11:55 AM.Comment
-
I have question. Is nextflex compatible with Ion proton sequencer?Do You provide adapters and other components separetly?Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment